SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Ada Lovelace

PatientAda Lovelace
Date of birth1990-12-10
IdentifiersMRN HR-NI031-SYN; SSN (made up) 000-31-6729
Document date2026-06-16
AuthorConstance Whitley-Adeyemi, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week follow-up of abnormal bleeding and pelvic pain, with the biopsy, MRI and PET-CT results and gynecologic oncology consultation today. [S]

History of Present Illness

Mrs. Lovelace returns two weeks after her first visit, on the day of her consultation with Dr. Lindgren-Osei. She stopped the opium tincture as agreed and takes oral morphine solution 5 mg with the oral syringe, about six doses a day; her average pelvic pain over the past week is 6 of 10, and she is not drowsy. The bleeding continues, lighter than before, with a watery discharge. She is a little less breathless on stairs since the iron infusion. Her bowels open every other day on senna and polyethylene glycol. She had the MRI a week ago and the PET-CT five days ago. She asked to hear all the results herself and plainly. [S]

ElementDetail
PainAverage 6 of 10; oral morphine 5 mg about six times a day; not drowsy
BleedingContinuing, lighter; watery discharge
AnemiaLess breathless since the iron infusion
BowelsEvery other day on laxatives
PreferenceWants the results told to her directly

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; no fever; weight steady
GenitourinaryPositiveLighter bleeding and watery discharge; no urinary symptoms
RespiratoryNegativeNo cough or hemoptysis
GastrointestinalNegativeBowels every other day; no nausea
PsychiatricPositiveAnxious about the results; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain0.5 mL four to six times a day as neededOral route2024-06-03 to 2026-06-02completedS
Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain5 mg every 4 hours as neededOral route2026-06-02activeS
Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow wholeevery 12 hoursOral route2026-06-16 to 2026-10-20completedS
Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911one spray as needed for suspected overdose; repeat after 2 to 3 minutes if neededNasal route2026-06-02activeS
Senna 8.6 mg tablet, two tablets by mouth at nighttwo tablets at nightOral route2026-06-02activeS
Polyethylene glycol 3350, 17 g in water by mouth once or twice a dayonce daily, up to twice dailyOral route2026-06-02activeS
Acetaminophen 500 mg tablet, two tablets by mouth three times a day1 g three times a dayOral route2026-06-02activeS
Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits750 mg on two occasions two weeks apartIntravenous route2026-06-02 to 2026-06-17completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-16Body height165cmS
2026-06-16Body weight54.2kgS
2026-06-16Body mass index (BMI) [Ratio]19.9kg/m2S
2026-06-16Systolic blood pressure106mm[Hg]S
2026-06-16Diastolic blood pressure66mm[Hg]S
2026-06-16Heart rate92/minS
2026-06-16Respiratory rate16/minS
2026-06-16Body temperature36.7CelS
2026-06-16Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-16Hemoglobin [Mass/volume] in Blood9g/dL12-15.5 g/dLLowS
2026-06-16Creatinine [Mass/volume] in Serum or Plasma0.66mg/dL0.57-1 mg/dLNormalS
2026-06-16Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma17U/L7-35 U/LNormalS
2026-06-16Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
2026-06-16Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2026-06-16Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M117mL/min/{1.73_m2}60 or moreNormalS
2026-06-16Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S

Physical Exam

Vital signs recorded on 2026-06-16; see the Vital Signs section. [S]

SystemFinding
GeneralPale and alert; blood pressure 106/66, pulse 92, weight 54.2 kg
Lymph nodesNo supraclavicular or inguinal lymph node enlargement
RespiratoryClear to auscultation
AbdomenSoft; mild suprapubic tenderness; no masses or liver enlargement

Problems

ProblemClinical statusVerificationCodeProvenance
Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intakeresolvedconfirmed N93.8S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairsactiveconfirmed D50.0S — Synthetic modern finding anchored to her documented final illness.
Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosisactiveconfirmed C53.0S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice.
Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extensionactiveconfirmed G89.3S — Synthetic modern diagnosis made at the second visit.
Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone suppliedactiveconfirmed Z79.891S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count (hemoglobin, white cells, neutrophils, platelets)Before each chemotherapy cycle and at each visitCompleted todayHemoglobin 9.0 g/dL; full count before the first cycle
LaboratoryCreatinine, eGFR and ALTBefore each cycleCompleted todayCreatinine 0.66 mg/dL, eGFR 117, ALT 17 U/L
LaboratoryTSH and free T4 on pembrolizumabBaseline, then every 6 weeksCompleted todayBaseline TSH 1.9 mIU/L, free T4 1.2 ng/dL before pembrolizumab
LaboratoryHIV, hepatitis B and hepatitis C before cancer treatmentOnce, before treatmentCompleted todayAll negative; hepatitis B surface antibody negative, so vaccination is due
LaboratoryFerritin after intravenous iron6 to 8 weeks after the infusionsDueDue 6 to 8 weeks after today's second infusion
ExaminationVaginal bleeding and transfusion needEvery visitCompleted todayContinuing, lighter; no transfusion needed
ImagingStaging: pelvic MRI and PET-CTAt diagnosisCompleted todayStage IVB by imaging; lung biopsy to confirm
SurveyPain intensity (0 to 10) and functionEvery visitCompleted todayAverage 6 of 10
Medication safetyOpioid adverse effects: sedation, confusion, nauseaEvery visitCompleted todayNo sedation, confusion or nausea
Medication safetyBowel regimen and constipationEvery visitCompleted todayEvery other day on senna and polyethylene glycol
Medication safetyNaloxone, locked storage, one prescriber, prescription monitoring checkAt each opioid changeCompleted todayNaloxone at home; locked storage; one prescriber; monitoring check clear
Medication safetySigns of opioid use disorderEvery visitCompleted todayNone
SurveyDepression screen (PHQ-9) and distressAt diagnosis and periodicallyUp to datePHQ-9 8 at the first visit; anxious today
ReferralSpecialist palliative careFrom diagnosis of advanced cancerCompleted todayFirst palliative care visit today
ReferralGynecologic oncology consultationOnce, at diagnosisCompleted todaySeen by Dr. Lindgren-Osei today

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Revised FIGO staging for carcinoma of the cervix uteri (Bhatla N, et al. Int J Gynaecol Obstet 2019;145:129-135) (2018); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021); Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); Patient-Clinician Communication: ASCO Guideline Update (Gilligan T, et al. J Clin Oncol 2026;44:1040-1057) (2026); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026)

Follow-up: Lung biopsy and pelvic radiation in the next ten days. Six-week review in four weeks. Next scheduled visit 2026-07-14: six-week review: bleeding and pain after palliative pelvic radiation, the first cycle of chemotherapy with pembrolizumab, blood counts, mood and opioid safety. [S]